GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » Price-to-Free-Cash-Flow

Astellas Pharma (TSE:4503) Price-to-Free-Cash-Flow : 23.55 (As of Dec. 12, 2024)


View and export this data going back to 1949. Start your Free Trial

What is Astellas Pharma Price-to-Free-Cash-Flow?

As of today (2024-12-12), Astellas Pharma's share price is 円1574.50. Astellas Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was 円66.86. Hence, Astellas Pharma's Price-to-Free-Cash-Flow Ratio for today is 23.55.

The historical rank and industry rank for Astellas Pharma's Price-to-Free-Cash-Flow or its related term are showing as below:

TSE:4503' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.47   Med: 18.16   Max: 56.24
Current: 23.55

During the past 13 years, Astellas Pharma's highest Price-to-Free-Cash-Flow Ratio was 56.24. The lowest was 10.47. And the median was 18.16.

TSE:4503's Price-to-Free-Cash-Flow is ranked better than
54.51% of 532 companies
in the Drug Manufacturers industry
Industry Median: 26.55 vs TSE:4503: 23.55

Astellas Pharma's Free Cash Flow per Share for the three months ended in Sep. 2024 was 円26.81. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was 円66.86.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Astellas Pharma was -15.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -26.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -6.70% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 2.40% per year.

During the past 13 years, Astellas Pharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 60.00% per year. The lowest was -42.70% per year. And the median was 6.85% per year.


Astellas Pharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for Astellas Pharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Price-to-Free-Cash-Flow Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.77 13.79 19.54 14.37 32.90

Astellas Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.11 24.46 32.90 34.83 24.63

Competitive Comparison of Astellas Pharma's Price-to-Free-Cash-Flow

For the Drug Manufacturers - General subindustry, Astellas Pharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Price-to-Free-Cash-Flow falls into.



Astellas Pharma Price-to-Free-Cash-Flow Calculation

Astellas Pharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1574.50/66.858
=23.55

Astellas Pharma's Share Price of today is 円1574.50.
Astellas Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円66.86.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Astellas Pharma  (TSE:4503) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Astellas Pharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines